Related Experiment Video

Updated: May 11, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

IRF4 promotes cell proliferation by JNK pathway in multiple myeloma

Sensen Zhang1, Jiaren Xu, Shuang Wu

  • 1Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing 210029, China.

Medical Oncology (Northwood, London, England)
|May 14, 2013
PubMed

Insights

Interferon regulatory factor 4 (IRF4) is crucial in multiple myeloma. Its presence indicates advanced disease and targeting IRF4 may inhibit cancer progression and induce cell death.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Interferon regulatory factor 4 (IRF4) is implicated in lymphoid and myeloid malignancies.
  • IRF4's specific role in multiple myeloma pathogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the expression and role of IRF4 in multiple myeloma.
  • To determine the correlation between IRF4 expression and disease progression.

Main Methods:

  • Immunohistochemical staining of bone marrow biopsy samples from multiple myeloma patients.
  • IRF4 gene silencing in myeloma cell lines.
  • Analysis of cell proliferation and apoptosis.
  • Investigation of the JNK/Jun pathway.

Main Results:

  • IRF4 expression was exclusively observed in plasma cells of multiple myeloma patients.
  • Higher IRF4 expression correlated with advanced disease stages (Durie-Salmon and International Staging System).
  • Silencing IRF4 inhibited myeloma cell proliferation and induced apoptosis, partly via the JNK/Jun pathway.

Conclusions:

  • IRF4 is a specific marker for plasma cells in multiple myeloma.
  • IRF4 plays a significant role in multiple myeloma development and progression.
  • Targeting IRF4 presents a potential therapeutic strategy for multiple myeloma.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...